kidney disease and semaglutide Safety Efficacy of in Patients With Chronic Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis Novo Nordisk's Star Diabetes &

7.2 episodes per 100 patient years of exposure, respectively)

These combinations target complementary pathways and may provide synergistic metabolic benefits

Despite the ability of GLP-1s to produce significant weight reduction and related health benefits, challenges such as GI side effects, risk of nutrient inadequacies, loss of muscle and bone mass, high costs, frequent discontinuation, and weight regain limit, the use of these drugs for long-term success in individuals and populations

With physician supervision, structured nutrition, and lifestyle integration, both agents can be powerful tools in long-term fat loss and health optimization